Safety and Efficacy of Fondaparinux in Renal Impairment

Area of Science:

• Pharmacology
• Nephrology
• Thrombosis and Hemostasis

Background:

• Renal impairment affects drug clearance and can increase risks associated with anticoagulants.
• Fondaparinux is a synthetic pentasaccharide anticoagulant with a different pharmacokinetic profile than low molecular weight heparins.

Purpose of the Study:

• To synthesize existing evidence on the safety and efficacy of fondaparinux in patients with impaired renal function.
• To assess fondaparinux's impact on preventing thrombosis and its associated bleeding risk in renally impaired individuals.

Main Methods:

• A systematic search of MEDLINE and Cochrane databases was conducted for studies on fondaparinux in renal failure or dialysis up to November 2014.
• Inclusion criteria focused on English-language articles involving patients with creatinine clearance <50 mL/min, excluding specific use cases and study types.
• Data synthesis included 4 cohort studies, 1 clinical trial, and 1 randomized clinical trial (RCT) subgroup analysis, totaling 3237 patients.

Main Results:

• Fondaparinux doses ranged from 1.25 mg to 2.5 mg daily across studies investigating prophylaxis or treatment.
• In the single RCT subgroup analysis comparing fondaparinux to enoxaparin, the composite outcome of safety and efficacy was significantly better with fondaparinux (P = .001).
• Across all included studies, 470 patients experienced thromboembolic events or death, and 169 experienced major bleeding.

Conclusions:

• The current body of evidence on fondaparinux in renally impaired patients is limited.
• Available data do not provide sufficient support for the routine use of fondaparinux in this patient population.
• Further research is needed to clarify the role of fondaparinux in managing thrombosis in patients with renal impairment.